TP53 and acute myeloid leukemia: Although p53 activation and Bcl-2 inhibition have been shown to reciprocally overcome resistance to each other in primary AML cells, at least in part, through the negative regulation of Mcl-1 by p53 [56], our results showed that the benefits of the venetoclax and ATO combination treatment in promoting apoptosis are efficacious irrespective of the p53 status.